DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Net Income
Bottom-line profit after all expenses, interest, and taxes.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$10.04M, compared with -$7.71M a year earlier. Trailing-twelve-month net income was -$35.1M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$36.82M (-12.4%) for the fiscal year ending Dec 2026, a step up from the -34.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.04M-14.9% QoQ
- Last fiscal yearDec 2025
- -$32.77M-34.0% YoY
- LTMMar 2026
- -$35.1M-30.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -30.3% | -40.4% | -10.1 pp |
| 1 year | -34.0% | -12.4% | +21.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (32.77M) USD
- Year-over-year change
- -34.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32.77M) | -34.0% |
| FY2024 | 2024-12-31 | (24.44M) | -26.1% |
| FY2023 | 2023-12-31 | (19.38M) | -41.7% |
| FY2022 | 2022-12-31 | (13.68M) | -0.6% |
| FY2021 | 2021-12-31 | (13.59M) | — |
Net Income vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 net income of -$35.1M is the 2nd highest of the 7 companies compared; the peer median is -$82.38M.
- Its year-over-year change of -30.0% is the 5th highest of 7, against a peer median of -18.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$20.51M | +54.7% | — | 8.8% | |
| LTM Mar 2026 | -$35.1M | -30.0% | — | — | |
| LTM Mar 2026 | -$39.95M | -162.9% | — | — | |
| LTM Mar 2026 | -$74.84M | -9.4% | — | 8418.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.93M | -26.6% | — | 871.8% |
| LTM Mar 2026 | -$122.54M | -335.9% | — | 612.7% | |
| LTM Jun 2026 | -$511.45M | -6.8% | — | 14191.2% | |
| Peer median (excluding DMAC) | -$82.38M | -18.0% | — | 871.8% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M |
| Selling, General & Admin | 4.88M | 6.16M | 8.16M | 7.62M | 9.78M |
| Operating Expenses | 13.65M | 14M | 21.27M | 26.68M | 34.4M |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | 43K |
| EBITDA | (13.54M) | (13.62M) | (19.31M) | (24.38M) | (32.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.65M) | (14M) | (21.27M) | (26.68M) | (34.4M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 2.3M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 82K | 353K | 1.93M | 2.27M | 1.66M |
| Income Before Tax | (13.56M) | (13.65M) | (19.34M) | (24.41M) | (32.74M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 28K | 28K | 43K | 30K | 28K |
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| EPS (Diluted) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| Weighted Avg Shares | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.